2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

Kay, Andrea; Saven, Alan; Carrera, Carlos J.; Carson, Dennis A.; Thurston, Don L.; Beutler, Ernest; Piro, Lawrence D.

doi:10.1200/jco.1992.10.3.371

Cited by 159 publications

(61 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other agents in this class include ethynyl uracil (Porter et al, 1992), decitabine (Richel et al, 1988) and the fludarabine analogue cladribine (Kay et al, 1992), all of which are currently under clinical investigation. Figure 4) has been the subject of intense research activity in recent years (Takemura and Jackman, 1997).…”

Section: Nucleoside Analoguesmentioning

confidence: 99%

New antimetabolites in cancer chemotherapy and their clinical impact

1998

Br J Cancer

136

View full text Add to dashboard Cite

Summary It is almost 50 years since antimetabolites were first found to have clinical antitumour activity, with Farber's discovery that aminopterin could cause remission in acute leukaemia. In the following 10 years, methotrexate, 6-mercaptopurine and 5-fluorouracil (5-FU) found their way into clinical practice. Subsequently, cytosine arabinoside was found to have activity in acute leukaemia, but, until recently, other significant developments have involved optimizing the efficacy of existing antimetabolites, including the use of leucovorin with methotrexate or 5-FU. Recently, new antimetabolites have become a fertile area for anti-cancer drug research. Gemcitabine (GEMZAR®) has emerged as an important new agent in several tumour types, including pancreatic, non-small-cell lung, bladder, breast and ovarian cancers. Capecitabine is an intriguing new prodrug, offering tumour selectivity and prolonged tumour exposure to 5-FU. More potent thymidylate synthase inhibitors have also emerged; raltitrexed is now commercially available for the treatment of colorectal cancer. Others under development include LY231514, which has other sites of action, hence the acronym MTA (multi-targeted antifolate). A novel target is glycinamide ribonucleotide formyltransferase (GARFT) and LY309887 and AG2034 are undergoing clinical investigation as GARFT inhibitors. A critical element with LY309887 appears to be co-administration of folate. It seems entirely possible that several novel antimetabolites will establish themselves in clinical practice in future for the treatment of solid tumours.

show abstract

Section: Nucleoside Analoguesmentioning

confidence: 99%

New antimetabolites in cancer chemotherapy and their clinical impact

1998

Br J Cancer

136

View full text Add to dashboard Cite

show abstract

“…[18][19][20][21][22] Initial trials with 2-CdA established a maximal tolerated dose of 0.1 mg/kg per day as a continuous intravenous infusion over 7 days 23 ; however, because of its long half-life, bolus, subcutaneous, and oral regimens have been equally effective. 7,8,12,13,[15][16][17][24][25][26][27] Reported toxicities consist primarily of myelosuppression and bacterial and opportunistic infections, [4][5][6][7][8][9][10][11][12][13][14][15][16][17] with less frequent occurrences of autoimmune hemolytic anemia 28 and neurotoxicity. 29 Rare reports of an increased incidence of second malignancies or transformation to aggressive NHL have not been confirmed.…”

Section: Conclusion 2-mentioning

confidence: 99%

“…2-Chlorodeoxyadenosine (2-CdA) (cladribine, Leustatin) is a deoxyadenosine purine nucleoside analog that is toxic to both proliferating and resting lymphocytes (for review, see Tallman and Hakimian 1 ), with activity in chronic lymphocytic leukemia (CLL), 2,3 lowgrade NHL, [4][5][6][7][8][9][10][11][12][13][14][15][16][17] and hairy cell leukemia (HCL). [18][19][20][21][22] Initial trials with 2-CdA established a maximal tolerated dose of 0.1 mg/kg per day as a continuous intravenous infusion over 7 days 23 ; however, because of its long half-life, bolus, subcutaneous, and oral regimens have been equally effective.…”

Section: Conclusion 2-mentioning

confidence: 99%

Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma

Blum¹,

Johnson²,

Niedzwiecki³

et al. 2006

Cancer

View full text Add to dashboard Cite

A H2O/dimethyl sulfoxide(DMSO) mixture was used as the coagulation bath for the wet‐spun process of acrylonitrile/ammonium itaconate copolymers fibers. Diffusion coefficient of DMSO in the protofibers prepared by acrylonitrile/ammonium itaconate copolymers was determined. It has been found that diffusion coefficient of DMSO outflow of the protofibers prepared by acrylonitrile/ammonium itaconate copolymers synthesized by the solution polymerization is highest compared with those of acrylonitrile/ammonium itaconate copolymers synthesized by H2O/DMSO mixture suspension polymerization and the aqueous suspension polymerization. With an increase of copolymer concentration in the dope, diffusion coefficient of DMSO decreases continuously. Diffusion coefficient of DMSO increases along with the bath temperature, but the changes of diffusion coefficient values are less prominent as temperature goes beyond 60°C. When DMSO concentration in the coagulation bath was 55 wt %, the value of the diffusion coefficient of DMSO was minimal. Diffusion coefficient of H2O increases with the jet stretch minus ratio increasing. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 100: 4447–4451, 2006

show abstract

“…A number of phase I and phase I/II studies have investigated the activity of 2CDA in white cell malignancies, the majority having been initiated by the Scripps clinic (Piro, L.D., 1992;Piro et al, 1990;Beutler et al, 1991;Piro et al, 1988; Kahn et al, 1991;Kay et al, 1992). These have shown that 2CDA has promising activity in lymphoid and myeloid malignancies of both high and low grade types.…”

mentioning

confidence: 99%

“…The group from the Scripps clinic have also recently described their experience of repeated courses of 2CDA (0.1 mg/kg/day over 7 days) in 40 patients with refractory low grade and transformed low grade non-Hodgkin's lymphoma (Kay et al, 1992 (Seela & Boureois, 1989;Soula, 1985). The drug was supplied as a sterile solution at a concentration of 2 mg ml-' in 0.9% NaCl.…”

mentioning

confidence: 99%